Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...

US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Stallergenes Greer, Shionogi Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer's ...

Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

There will be another ‘COVID’. Governments are planning for it, but how coordinated is that planning, and how resilient will ...

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

AN Venture Partners has closed its first fund, a $200 million vault for biotechs worldwide, with particular emphasis on ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...